dc.contributor.author | Kosmidis, Paraskevas A. | en |
dc.contributor.author | Syrigos, K. | en |
dc.contributor.author | Kalofonos, H. P. | en |
dc.contributor.author | Dimopoulos, M. A. | en |
dc.contributor.author | Skarlos, Dimosthenis V. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Boukovinas, I. | en |
dc.contributor.author | Bafaloukos, Dimitrios | en |
dc.contributor.author | Pectasides, Dimitrios | en |
dc.contributor.author | Bacoyiannis, Charalambos | en |
dc.contributor.author | Fountzilas, George | en |
dc.creator | Kosmidis, Paraskevas A. | en |
dc.creator | Syrigos, K. | en |
dc.creator | Kalofonos, H. P. | en |
dc.creator | Dimopoulos, M. A. | en |
dc.creator | Skarlos, Dimosthenis V. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Boukovinas, I. | en |
dc.creator | Bafaloukos, Dimitrios | en |
dc.creator | Pectasides, Dimitrios | en |
dc.creator | Bacoyiannis, Charalambos | en |
dc.creator | Fountzilas, George | en |
dc.date.accessioned | 2018-06-22T09:53:49Z | |
dc.date.available | 2018-06-22T09:53:49Z | |
dc.date.issued | 2012 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/42044 | |
dc.description.abstract | Aim: The purpose of this study was to compare two single agents paclitaxel (intravenous) versus vinorelbine (oral) in non-small cell lung cancer (NSCLC) patients with performance status (PS):2. Patients and Methods: The patients were randomized to receive either oral vinorelbine 60 mg/m 2 on days I, 8, 15 every 4 weeks for 4 cycles (group A) or paclitaxel 90 mg/m 2 intravenously for 1 h on days 1, 8, 15 every 4 weeks for a total of 4 cycles (group B). Results: Among the 74 eligible patients (36 in arm A and 38 in arm B) in arm A, two (6%) had a partial response (95% Cl, 0.7-18.7) and 5 (14%) had stable disease (95% CI, 4.7-29.5). In arm B, five (13%) had a partial response (95% CI, 4.4-28.1) and 7 (18%) had stable disease (95% CI, 7.7-34.3). No significant difference was found in terms of clinical benefit between the two groups after two cycles of treatment except for appetite in favour of paclitaxel (p=0.01). Median survival was 3.1 months (95% CI, 2.2-4.0) for arm A and 5.1 months (95% CI, 2.7-7.6) for arm B (p=0.95). Toxicity was mild and only alopecia was more profound in the patients of arm B (p=0.008). Conclusion: No significant difference was found in clinical benefit between PS:2 NSCLC patients treated with either vinorelbine or paclitaxel. | en |
dc.language.iso | eng | en |
dc.source | Anticancer Research | en |
dc.subject | Article | en |
dc.subject | Cancer chemotherapy | en |
dc.subject | Human | en |
dc.subject | 80 and over | en |
dc.subject | Adenocarcinoma | en |
dc.subject | Aged | en |
dc.subject | Brain neoplasms | en |
dc.subject | Humans | en |
dc.subject | Adult | en |
dc.subject | Controlled study | en |
dc.subject | Female | en |
dc.subject | Major clinical study | en |
dc.subject | Middle aged | en |
dc.subject | Advanced cancer | en |
dc.subject | Chemotherapy | en |
dc.subject | Disease progression | en |
dc.subject | Neoplasm staging | en |
dc.subject | Priority journal | en |
dc.subject | Alopecia | en |
dc.subject | Anemia | en |
dc.subject | Antineoplastic combined chemotherapy protocols | en |
dc.subject | Diarrhea | en |
dc.subject | Leukopenia | en |
dc.subject | Local | en |
dc.subject | Navelbine | en |
dc.subject | Neoplasm recurrence | en |
dc.subject | Neutropenia | en |
dc.subject | Stomatitis | en |
dc.subject | Thrombocytopenia | en |
dc.subject | Treatment outcome | en |
dc.subject | Vinblastine | en |
dc.subject | Vinorelbine | en |
dc.subject | Fever | en |
dc.subject | Liver toxicity | en |
dc.subject | Pain | en |
dc.subject | Randomized controlled trial | en |
dc.subject | Lung neoplasms | en |
dc.subject | Lung non small cell cancer | en |
dc.subject | Survival rate | en |
dc.subject | Carcinoma | en |
dc.subject | Male | en |
dc.subject | Bleeding | en |
dc.subject | Vomiting | en |
dc.subject | Follow-up studies | en |
dc.subject | Lymphatic metastasis | en |
dc.subject | Liver neoplasms | en |
dc.subject | Multiple cycle treatment | en |
dc.subject | Drug withdrawal | en |
dc.subject | Squamous cell | en |
dc.subject | Paclitaxel | en |
dc.subject | Bone neoplasms | en |
dc.subject | Histamine h2 receptor antagonist | en |
dc.subject | Pruritus | en |
dc.subject | Non-small-cell lung | en |
dc.subject | Lymphocytopenia | en |
dc.subject | Rash | en |
dc.subject | Clinical benefit | en |
dc.subject | Large cell | en |
dc.subject | Lung infection | en |
dc.subject | Non-small cell lung cancer | en |
dc.subject | Performance status of 2 | en |
dc.subject | Small cell lung carcinoma | en |
dc.title | Vinorelbine versus paclitaxel for patients with advanced non-small cell lung cancer (NSCLC) and a performance status of 2 | en |
dc.type | info:eu-repo/semantics/article | |
dc.description.volume | 32 | |
dc.description.issue | 1 | |
dc.description.startingpage | 175 | |
dc.description.endingpage | 181 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Kalofonos, H. P. [0000-0002-3286-778X] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |
dc.gnosis.orcid | 0000-0002-3286-778X | |